Parexel buying functional service provider ExecuPharm for undisclosed amount

Boston CRO giant Parexel ($PRXL) said it is buying biopharma functional service provider ExecuPharm for an undisclosed amount. 

The deal is expected to close in the next three weeks, the company said. Financial terms weren’t disclosed.

“Functional services represent an established and growing model within the biopharmaceutical industry,” Josef von Rickenbach, Parexel’s chairman and CEO, said in a statement. “With ExecuPharm, Parexel will expand and strengthen our existing functional services offering and capabilities to meet the growing market demand while allowing our clients to fulfill all of their clinical development outsourcing needs through a single company.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

King of Prussia, PA-based ExecuPharm, which was established in 1995, provides clients with qualified professionals across functional areas such as clinical monitoring or study management, along with associated activities including training, line management, performance management and policy administration.

News of the transaction follows the July resignation of Parexel’s chief financial officer and senior vice president, Ingo Bank, who the company said left to take a position at another company. Parexel has been in a cost-cutting mode since last year, when it said it would look to shed about 850 jobs in an attempt to save between $20 million and $30 million.

In late August, in an apparently unrelated matter, Parexel notified the SEC in a filing that it would be late in submitting its 10-K performance form as it has found out that one of its employees, who worked “in one of the Company’s international operations,” has been misusing its money.

Related Articles:
Parexel delays 10-K filing as it looks into ‘misappropriation of corporate funds’ 
Parexel predicts strong growth amid ‘paradigm shifts’ in biopharma 
Parexel CFO, SVP Ingo Bank quits just weeks before Q4 results

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.